Bupropion Hydrochloride; Naltrexone Hydrochloride Patent Expiration
Bupropion Hydrochloride; Naltrexone Hydrochloride is used for chronic weight management and treating overweight or obesity, as well as to address blood glucose parameters and major depressive disorder in patients. It was first introduced by Nalpropion Pharmaceuticals Llc
Bupropion Hydrochloride; Naltrexone Hydrochloride Patents
Given below is the list of patents protecting Bupropion Hydrochloride; Naltrexone Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Contrave | US10231964 | Compositions and methods for weight loss in at risk patient populations | Jul 02, 2034 | Nalpropion |
| Contrave | US10307376 | Methods for administering weight loss medications | Nov 08, 2027 | Nalpropion |
| Contrave | US10403170 | Methods of treating overweight and obesity | Jun 05, 2033 | Nalpropion |
| Contrave | US10828294 | Compositions and methods for weight loss in at risk patient populations | Jul 02, 2034 | Nalpropion |
| Contrave | US10835527 | Compositions and methods for reducing major adverse cardiovascular events | Jul 02, 2034 | Nalpropion |
| Contrave | US11033543 | Methods of providing weight loss therapy in patients with major depression | Jan 10, 2031 | Nalpropion |
| Contrave | US11139056 | Methods of treating overweight and obesity | Jun 05, 2033 | Nalpropion |
| Contrave | US11278544 | Compositions for affecting weight loss |
Apr 21, 2024
(Expired) | Nalpropion |
| Contrave | US11324741 | Methods for treating visceral fat conditions | May 29, 2029 | Nalpropion |
| Contrave | US11998542 | Compositions and methods for reducing major adverse cardiovascular events | Jul 02, 2034 | Nalpropion |
| Contrave | US7375111 | Compositions for affecting weight loss | Mar 26, 2025 | Nalpropion |
| Contrave | US7462626 | Compositions for affecting weight loss |
Jul 20, 2024
(Expired) | Nalpropion |
| Contrave | US8088786 | Layered pharmaceutical formulations | Feb 03, 2029 | Nalpropion |
| Contrave | US8318788 | Layered pharmaceutical formulations | Nov 08, 2027 | Nalpropion |
| Contrave | US8722085 | Methods for administering weight loss medications | Nov 08, 2027 | Nalpropion |
| Contrave | US8815889 | Compositions and methods for increasing insulin sensitivity |
Jul 20, 2024
(Expired) | Nalpropion |
| Contrave | US8916195 | Sustained release formulation of naltrexone | Feb 02, 2030 | Nalpropion |
| Contrave | US9107837 | Sustained release formulation of naltrexone | Jun 04, 2027 | Nalpropion |
| Contrave | US9125868 | Methods for administering weight loss medications | Nov 08, 2027 | Nalpropion |
| Contrave | US9248123 | Methods of providing weight loss therapy in patients with major depression | Jan 13, 2032 | Nalpropion |
| Contrave | US9633575 | Methods of treating overweight and obesity | Jun 25, 2033 | Nalpropion |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳